1. Medtech Insight
  2. >>Business
  3. >>Deals

Stroke Prevention For TAVR – And, Perhaps, Beyond

Although TAVR-related stroke rates have been diminishing, it remains a devastating complication of the procedure. Two companies with devices to deflect or collect emboli are embarking on IDE trials that they hope will make cerebral embolic protection a standard of care in TAVR and perhaps other cardiac surgeries, as it already is in carotid artery stenting.

Transcatheter aortic valve replacement (TAVR) is a rising alternative to surgical aortic valve replacement (SAVR) in otherwise inoperable or high-risk patients with severe aortic stenosis. Its penetration into aortic valve replacement is growing fast, extending to younger and lower-risk patients, and Morgan Stanley recently predicted a $7.4 billion TAVR market by 2025. Like other left-sided heart procedures, TAVR carries a stroke risk because debris can be released into the aorta as the new valve is placed. (See[A#2014700132]and Also see "TAVR Market: Next-Generation Devices Seek To Optimize Outcomes" - Medtech Insight, 28 March, 2014..)

Although results from the ADVANCE study published in the July 21, 2015, issue of the Journal of the American College...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Apreo Health Raises $130M, First Patient Treated In US Clinical Trial

 
• By Natasha Barrow

Apreo Health CEO Karun Naga talks to Medtech Insight about the company’s intentions for its Series B funding. The Breathe-3 clinical trial and early commercialization activities, involving physician education, are top priorities.

Exact Sciences Reveals Thinking On CRC Liquid Biopsy After Freenome Deal

 
• By Natasha Barrow

Exact Sciences has entered into an exclusive licensing agreement with Freenome, stipulating clinical benchmarks and a first-line rating in the USPSTF guidelines. Medtech Insight interviewed screening CMO Paul Limburg about CRC screening and Exact’s strategy on liquid biopsy.

Deals Shaping The Medtech And Diagnostics Industries, July 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during July 2025. Data courtesy of Biomedtracker.

Fresh Off $100M IPO, Carlsmed Plans For Growth, 2026 Launch Of Customized Cervical Fusion Implant

 
• By Marion Webb

Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.

More from Business

Biden-Era Device Trial Snapshot Pilot Halted Amid DEI Policy Shift

 
• By Elizabeth Orr

The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.

Fresh Off $100M IPO, Carlsmed Plans For Growth, 2026 Launch Of Customized Cervical Fusion Implant

 
• By Marion Webb

Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.